Oric Pharmaceuticals, Inc.
ORICDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ORIC Earnings Report
EPS Est: $-0.36 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ORIC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rinzimetostat | Phase 3 | Metastatic Castration Resistant Prostate Cancer | - | - |
ORIC-114 | Phase 2 | Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Oric Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Oric Pharmaceuticals, Inc.'s (ORIC) pipeline across Phase 3, Phase 2. Its lead program is Rinzimetostat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oric Pharmaceuticals, Inc.'s next FDA catalyst?→
Oric Pharmaceuticals, Inc.'s (ORIC) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORIC biotech catalysts?→
Add ORIC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oric Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.